Kornimate/medical-research-clean huggingface dataset:
screening for studies on retinovascular diseases

Conditions: Diabetic Retinopathy; Macular Degeneration; Pathologic Neovascularization; Retinal Disease

Summary: this screening protocol is designed to help recruit patients for national eye institute (nei) studies of the retina, such as diabetic retinopathy and macular degeneration. patients must meet the specific criteria of a research study, and this protocol serves as a first step for admitting patients to a retinal disease study. candidates will undergo a medical history and comprehensive eye examination. the eye examination includes dilation of the pupils to fully examine the retina. in some studies, photographs of the eye are required. this is done using fluorescein angiography. in this procedure, a dye called sodium fluorescein is injected into the blood stream through a vein. after the dye reaches the blood vessels of the eye, photographs are taken of the retina. other diagnostic procedures may include physical examination, questionnaires, routine laboratory tests and other standard or specialized tests, as needed. when the screening is completed, patients will be informed of their options to participate in a study. patients who are ineligible for a current study will be informed of alternative treatments or options. no treatment is offered under this protocol.

this protocol is designed for the screening of patients with presumed retinovascular diseases. it serves as a first step for individuals who may be eligible and wish to participate in national eye institute clinical research studies of retinovascular diseases. each individual will be thoroughly evaluated during the screening process to determine if they are suitable candidates for inclusion in any of the national eye institute ongoing studies. the screening evaluation will include past and current medical histories and an appropriate physical examination, namely a comprehensive eye exam. other routine diagnostic procedures and tests may also be completed in order to help determine a subject's eligibility. these tests and procedures are of minimal risk and will be described in more detail in section iii: "study procedures." once the screening process is completed and their eligibility is assessed, the subjects will be informed of their options to participate in one or more of the current clinical research studies. if no appropriate protocol is identified, recommendations for other treatment options may be given to the individual, their primary doctor, or referring physician.

Eligibility criteria:
* inclusion/exclusion criteria inclusion and exclusion criteria vary with the particular protocol for which a patient is being screened. in addition to those diagnoses currently under study, subjects with unknown conditions that require the establishment of a diagnosis may be eligible for inclusion in this study. all studies of retinovascular diseases require the subject to have minimum age of 18 years in both men and women.

Keywords: diabetic retinopathy age-related macular degeneration neovascularization macular degeneration retinal disease diabetes
preoperative analgesia: the effectiveness of the peng block in patients with hip fractures

Conditions: Hip Fracture Surgeries

Summary: the aim is to provide effective preoperative analgesia in patients undergoing surgical procedures due to hip fractures by administering a pericapsular nerve group (peng) block under ultrasound guidance. this approach seeks to increase patient satisfaction, reduce analgesic requirements, enable earlier discharge, and decrease morbidity and mortality.


Eligibility criteria:
inclusion criteria: * patients undergoing hip farcture surgery exclusion criteria: * chronic analgesics consumption * patients contraindicated for neuraxial anesthesia * alcohol and drug addiction * allergies to local anesthetics and opioids * patients who refuses to participate in the study

Keywords: analgesia peng block hip fracture
molecular diagnosis and risk stratification of sepsis

Conditions: Sepsis

Summary: background: sepsis is a major cause of in-hospital morbidity and mortality. current tools available to the clinician to initiate therapy of patients with sepsis mainly comprise of symptom classification systems and culture techniques, which provide aspecific and slow information. objective: the ultimate goal of this program is to assist the physician at the bedside in tailoring the treatment of an individual patient suffering from sepsis by generating rapid molecular information about the causative pathogen and the host response. deliverables: rapid tests ("sample-in-result-out") that can be used by health care personnel at or close to the bedside and that provide rapid information (within two hours) about the presence or absence of sepsis, the causative pathogen and the risk of the individual patient for sepsis complications and death. design: the program is organized into four work packages (wps) along a clinical, discovery and technology platform. in wp1 two university hospitals will enroll 7500 patients admitted to the intensive care unit during the first 3 years of the project; 25% - 40% of these patients will have or will develop sepsis. in wp2 (pathogen detection), blood obtained from these patients will be used to develop rapid, fully automated dna-based bedside tests that identify microorganisms and also provide information about their resistance to antibiotics. in wp3 (host response), rna from blood cells will be analyzed to find novel biomarkers and to develop rapid and easy to perform tests that provide information about the risk profile of the patient. in addition, plasma levels of selected protein biomarkers will be measured for comparison of their value with that of the identified leukocyte molecular signatures. wp4 is responsible for the ict management of the project. the clinical platform (covered by wp1 and wp4) delivers patient data and biological samples to the discovery and technology platforms. the discovery platform (covered by wp2 and wp3) uses patient data and biological samples to develop tests for detection of the infectious agent causing sepsis and for stratification of patients according to their risk for sepsis complications, including death. the results generated within the discovery platform will be delivered to the technology platform. the technology platform (part of wp2 and wp3) has the specific aim to develop rapid assays that run on a fully automated (micro)fluidics platform that is so easy to operate that it can be used in decentralized settings such as (close to) the icu. the developed assays will make use of the knowledge generated in the discovery platform.


Eligibility criteria:
inclusion criteria: * all patients\> 18 years in the intensive care units of the amc amsterdam and umc utrecht. exclusion criteria: * elective cardiac surgery patients with an uncomplicated stay.

Keywords: sepsis pneumonia peritonitis biomarkers transcriptomics pathogen detection
ultrasound-guided genicular nerve block with phenol for the treatment of chronic pain due to knee osteoarthritis

Conditions: Osteoarthritis, Knee; Chronic Pain

Summary: osteoarthritis (oa) is one of the most frequent causes of chronic pain, often intense, debilitating and responsible for a large percentage of the elderly. the disease affects about 10% of adults and the knees are the most affected joints. the diagnosis of oa in the knee is predominantly clinical, and can be confirmed by radiological examination. systemic drugs are indicated before invasive procedures, but pharmacological therapies may offer limited benefits. thermal radiofrequency lesions of genicular nerves has been used to relieve chronic knee pain, as adjuvant therapy, but with high costs and low availability in the public system. the use of phenol for peripheral analgesic blocks has emerged as a good option and at low cost and can be used in any service of pain treatment. the aim of the study is to evaluate the efficacy of 6% phenol for ultrasound-guided genicular nerves neurolysis for the treatment of patients with chronic knee pain due to osteoarthritis. methods: a prospective study will be carried out with 15 patients with chronic pain (more than 4 months) and diagnosis of arthrosis by imaging, with pain intensity greater than 4 (from zero to 10) that will be submitted to ultrasound-guided genicular nerves block. the test block will be performed with 0.25% -1,5 ml bupivacaine on each nerve. patients who present pain improvement\> 50% will undergo neurolysis of genicular nerves with 1,5 ml of 7% phenol in each of the genicular nerves. after the procedure, the patients will be evaluated for 3 months in relation to the intensity of pain at rest and movement and duration of analgesia provided by the intervention, range of movements and functionality of the knee joint.


Eligibility criteria:
inclusion criteria: * signature of the free, informed consent form * age over 18 years old * knee pain for more than six months without improvement with clinical treatment * clinical and imaging diagnosis (radiography) of knee osteoarthritis * moderate pain intensity (pain greater than 4, by the numerical scale). exclusion criteria: * cognitive impairment or psychiatric disease * other causes of knee pain (trauma, complex regional pain syndrome) * puncture site infection * coagulopathy or use of anticoagulant.
role of oxygen for vascular dysfunction

Conditions: Endothelial Dysfunction; FMD; IMT; Microcirculation; Oxygen Pressure; Carbon Dioxide Pressure; Oxygen Saturation; Forced Expiratory Volume After 1 Second

Summary: hypoxemia may contribute increased morbidity and mortality in chronic obstructive pulmonary disease (copd) patients. we aim to characterize the role of acute and chronic hypoxemia for vascular function. for this purpose we measure capillary oxygen concentration and vascular. vascular function is assessed by flow-mediated dilation oft he brachial artery, forearm blood flow and laser doppler perfusion imaging. we hypothesize that hypoxemia leads to impaired vascular function.


Eligibility criteria:
inclusion criteria: * stable coronary artery disease * stable chronic obstructive pulmonary disease exclusion criteria: * acute myocardial infarction within 30 days * acute exacerbated copd within 30 days * acute infections * severe acute or chronic renal failure * severe heart failure * atrial fibrillation * severe cardiac arrhythmia * hypotension * active malignant disease * active rheumatic disease * pulmonary hypertension with vasoactive therapy

Keywords: chronic obstructive pulmonary disease coronary artery disease endothelial function
drug-drug interaction study to evaluate the effect of isis 681257 on warfarin

Conditions: Elevated Lipoprotein(a); Cardiovascular Diseases

Summary: this is a single center, open label, single sequence, two-treatment, two-period drug-drug interaction study to evaluate the effect of multiple doses of isis 681257 on the pharmacokinetics of a single dose of warfarin.


Eligibility criteria:
inclusion criteria: * motivated and available for duration of study and willing to adhere to protocol * males who are unable to procreate or agree to contraception throughout study * females who are postmenopausal or surgically sterile * bmi between 18.5 and 30 kg/m2 * weighing greater than or equal to 50kg * normal lab results * no known diseases or significant findings on physical exam exclusion criteria: * females of childbearing potential * reactions/infection at injection site * hypersensitivity to any drugs or similar drugs to those used in the study * conditions or disease that may interfere with study drug * any significant diseases * known history or familial history of bleeding disorders * drug dependency or abuse * illness within 28 days * previous exposure to other investigational drug within 28 days * blood donations within 28 days
comparative antiresorptive efficacy discontinuation of denosumab

Conditions: Osteoporosis, Postmenopausal; Osteoporosis

Summary: osteoporosis remains a significant healthcare burden for the united states. current fda-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene. denosumab is a fully human monoclonal antibody that specifically binds to receptor activator of nuclear factor kappa-b ligand (rankl). denosumab potently suppresses osteoclastic activity but bone turnover rapidly normalizes and bone turnover marker levels can rebound above baseline levels after the drug is discontinued. this study will help us determine the optimal duration and relative efficacy of two oral antiresorptive medications that are fda-approved for treatment of postmenopausal osteoporosis (alendronate and raloxifene) in preventing the rebound increase in bone turnover that occurs after denosumab discontinuation.


Eligibility criteria:
inclusion criteria: * women aged 45+ * postmenopausal * osteoporotic with high risk of fracture as per national osteoporosis foundation guidelines exclusion criteria: * no significant previous use of bone health modifying treatments * hip fracture within one year of enrollment * known congenital or acquired bone disease other than osteoporosis * significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease * abnormal calcium or parathyroid hormone level * serum vitamin d \<20 ng/dl * anemia (hematocrit \<32%) * history of malignancy (except non-melanoma skin carcinoma) * excessive alcohol use or substance abuse * extensive dental work involving extraction or dental implant within the past 6 months or in the upcoming 12 months * known contraindications to denosumab, alendronate, or raloxifene
jeffquit group therapy program for smoking cessation in patients with a history of cancer

Conditions: Current Smoker; Malignant Neoplasm

Summary: this pilot clinical trial studies how well the "jeffquit" group therapy program works in enabling patients with a history of cancer to quit smoking. the jeffquit program uses group therapy to provide psychological support and address the mental need for smoking, the habit or routine it creates, and the physical need for nicotine. it is not yet known how well the jeffquit program will work in helping patients with a history of cancer to stop smoking.

primary objectives: i. to assess the initial effectiveness of the jeffquit program on smoking cessation in cancer patients. ii. to assess the quality of life improvements related to the jeffquit smoking cessation program in cancer patients. outline: patients undergo three, 1-hour group therapy sessions held by a jeffquit practitioner over a 1-month period. patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. the jeffquit counselor is available for additional individual support as needed. after completion of study, patients are followed up at 6 months.

Eligibility criteria:
inclusion criteria: 1. history of cancer 2. current smoker 3. willing to provide consent and participate in the jeffquit program 4. referral by a kimmel cancer center provider exclusion criteria: 1. any significant active medical disorder or physical condition that could reasonably be expected to interfere with the ability of the patient to quit smoking as determined by the principal investigator (pi) 2. currently participating in another smoking cessation program 3. currently receiving chemotherapy or radiation therapy that would interfere with their ability to participate in the jeffquit program 4. patients with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate 5. patients with current alcohol or drug abuse 6. enrollment in active clinical trial/ experimental therapy within the prior 30 days 7. are in the terminal stages of illness
evaluation of efficacy and safety of ialuset cream and gauze in second-degree burns on child

Conditions: Second-degree Burn of Children

Summary: observational retrospective monocentric study occured in the univeristy hospital center of bensançon the department of pediatric surgery. data of patients treated in the hospital between january 2016 and january 2019 have been collected.

coordinator investigator have put in place a protocol care for children with second degree burns since 2016. it consists in detersion and cleaning of wound, application of ialuset cream and gauzepad (hyaluronic acid) during 21 days. after 21 days if patients are not healed, physician consider to perform grafting

Eligibility criteria:
inclusion criteria: * second-degree burns * less than 20% of the body surface * less than 15 years old * treated within 24 hours * 1st line of treatment with ialuset * treated at the center between 2016 and 2019 exclusion criteria: * patient who refused data collection
dynepo infrequent dosing study

Conditions: Anemia; Kidney Failure

Summary: the purpose of this study is to demonstrate non-inferiority of efficacy between twice weekly and once weekly dose schedule of dynepo in previously erythropoietin (epo)-naive patients, as measured by haemoglobin at week 24 and secondly to demonstrate the non-inferiority of efficacy between once weekly and once every two weeks dose schedules of dynepo in patients previously stable on epo, as measured by hb over weeks 16 to 24.


Eligibility criteria:
inclusion criteria: * aged at least 18 years with chronic kidney disease (kidney disease outcomes quality initiative \[kdoqi\] stage iii-v). * stable on and taking doses \<= 10,000 iu/week of subcutaneous (sc) epo or requiring initiation of epo. * transferrin saturation \>= 20% and ferritin \>= 100 ng/ml. exclusion criteria: * uncontrolled hypertension. * requiring doses of epo \> 10,000 iu/week. * two or more doses of prescribed epo treatment missed ot withheld by physician order in the 14 days immediately prior tp randomisation in the study. * active bleeding disorder (diathesis) (for example, gastrointestinal or genitourinary tract bleeding). * treatment with immunosuppressive drugs (other than corticosteroids for a chronic condition) in the 30 days immediately prior to randomisation in the study. * androgen therapy in the 30 days immediately prior to randomisation in the study. * known human immunodeficiency virus(hiv)infection. * history of hypersensitivity to epo therapy or to any of the excipients of dynepo.

Keywords: chronic
effects of antagonizing the ghrelin receptor on brain food cue reactivity in obesity

Conditions: Obesity and Overweight

Summary: the naturally occurring peptide hormone liver-expressed antimicrobial peptide 2 (leap2) in an antagonist/inverse agonist towards the ghrelin receptor. ghrelin administration has previously been shown to increase food cue reactivity in brain regions related to appetite and reward using functional mri scans. the aim of this clinical study is to investigate the effects of leap2 infusion on food cue reactivity in brain regions related to appetite and reward. since leap2 is an antagonist/inverse agonist towards the ghrelin receptor we hypothesize, that leap2 infusion will decrease food cue reactivity in the above-mentioned regions compared to placebo infusion. participants with obesity (bmi 30-50 kg/m2) will be included and complete two experimental days with either leap2 or placebo infusion in a randomized crossover manner. on experimental days, participants will undergo a mri scan with functional and anatomical modalities. the study will attribute to gain a deeper understanding of the ghrelin system and its interaction with appetite regulation.


Eligibility criteria:
inclusion criteria: * age between 18 and 60 years at the time of inclusion * body mass index 30-50 kg/m2 * men * informed consent exclusion criteria: * anaemia (haemoglobin below normal range) * alanine aminotransferase (alat) and/or aspartate aminotransferase (asat) \>2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s) * nephropathy (serum creatinine above normal range and/or albuminuria) * glycated haemoglobin (hba1c) ≥48 mmol/mol and/or type 2 diabetes requiring medical treatment * regular tobacco smoking or use of other nicotine-containing products * claustrophobia * any ongoing medication that the investigator evaluates would interfere with trial participation. * any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
movement dynamics of knee osteoarthritis and total knee replacement

Conditions: Knee Osteoarthritis; Total Knee Replacement

Summary: this research aims to explore differences in walking and functional movement mechanics, exercise response, and physical activity between people with osteoarthritis (oa), those who have undergone total joint replacement, and healthy individuals.

people living with oa tend to be less physically active than those without the disease, which is often due to pain, stiffness and joint instability. this reduction in physical activity can lead to additional health problems down the line. when the disease becomes severe, joint replacement surgeries are sometimes performed to relieve pain and improve individuals' quality of life. however, despite reducing pain, there is little evidence to show that joint replacement surgeries encourage individuals to return to healthy physical activity levels. reasons for the lack of change may include a failure to address unhealthy walking and movement patterns which could still be causing pain and instability and reduced physical fitness levels. by investigating these reasons, we hope that findings from this study will help to inform future interventions that improve clinical outcomes and quality of life for individuals with oa and post-joint replacement.

Eligibility criteria:
inclusion criteria: * diagnosed symptomatic bilateral or unilateral knee osteoarthritis, self-reported ability to walk without an aid for 10 minutes and to ascend and descend stairs, no neurological conditions or other musculoskeletal pathology/injury which would impact walking gait. exclusion criteria: * unable to walk at 0.8 m/s, exclusion based on imo screening, non-english speaking, lacking ability to consent.